Literature DB >> 9396076

Anti-inflammatory action of methimazole.

J F Lagorce1, T Moulard, A Rousseau, F Comby, J Buxeraud, C Raby.   

Abstract

The anti-inflammatory activity of 1-methylimidazole-2-thiol (methimazole), the most widely used antithyroid drug, was investigated. Methimazole had a marked inhibitory action on prostaglandin H synthase (IC50 = 10 mumol/l), inhibiting the peroxidase (IC50 = 330 mumol/l), although the cyclo-oxygenase was slightly activated. Methimazole was less potent than indometacin (IC50 = 1.7 mumol/l) on prostaglandin H synthase, but was more potent than acetylsalicylic acid (IC50 = 160 mumol/l). Methimazole has been found to trap superoxide (O2.-) radicals and to decrease the level of blood prostaglandin E2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396076     DOI: 10.1159/000139525

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Mitochondrial biotransformation of omega-(phenoxy)alkanoic acids, 3-(phenoxy)acrylic acids, and omega-(1-methyl-1H-imidazol-2-ylthio)alkanoic acids: a prodrug strategy for targeting cytoprotective antioxidants to mitochondria.

Authors:  Kurt S Roser; Paul S Brookes; Andrew P Wojtovich; Leif P Olson; Jalil Shojaie; Richard L Parton; M W Anders
Journal:  Bioorg Med Chem       Date:  2010-01-15       Impact factor: 3.641

2.  Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis.

Authors:  Weihao Shi; Yijun Huang; Zhou Yang; Liang Zhu; Bo Yu
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

3.  Methimazole Inhibits the Expression of GFAP and the Migration of Astrocyte in Scratched Wound Model In Vitro.

Authors:  Lina Zhao; Xianyu Zhang; Chunhai Zhang
Journal:  Mediators Inflamm       Date:  2020-04-13       Impact factor: 4.711

4.  The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial.

Authors:  Wismandari Wisnu; Idrus Alwi; Nafrialdi Nafrialdi; Kuntjoro Harimurti; Tjokorda Gede D Pemayun; Sri Widia A Jusman; Dewi Irawati S Santoso; Alida R Harahap; Suhendro Suwarto; Imam Subekti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-20       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.